Zosano Announces Inducement Grant for Georgia Erbez, Chief

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Zosano Announces Inducement Grant for Georgia Erbez, Chief Business Officer

FREMONT, Calif., Sept. 09, 2016 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ: ZSAN ), an emerging CNS company focusing on providing rapid symptom relief to patients using the Company’s proprietary transdermal delivery system, today announced that it has approved an inducement grant of options to purchase 252,000 shares of the Company’s common stock with an exercise price of $0.77 per share, the closing price on September 7, 2016, to Georgia Erbez, the Company's recently hired Chief Business Officer. The stock options have a ten year term and vest over four years, with one-fourth vesting on the first anniversary of the date of grant and the remaining three-fourths vesting in equal monthly installments thereafter.

The grant was made as an inducement that was a material component of Ms. Erbez's compensation and subsequent acceptance of employment with the Company and was granted as an employment inducement award pursuant to Nasdaq Listing Rule 5635(c)(4) approved by the Company's Compensation Committee.

About Zosano Pharma

Zosano Pharma Corporation is an emerging CNS company focusing on providing rapid symptom relief to patients using known therapeutics and altering their delivery profile using the Company’s proprietary transdermal delivery system. The Company’s goal is to make transdermal drug delivery a standard of care for delivering drugs requiring fast onset of action. Zosano Pharma has developed its proprietary transdermal delivery system to administer novel formulations of existing drugs through the skin for the treatment of a variety of indications.  The Company believes that its transdermal delivery system offers rapid and consistent drug delivery combined with ease of use.  The Company is focused on developing products that deliver established molecules with known safety and efficacy profiles for markets where patients remain underserved by existing therapies.  Zosano Pharma anticipates that many of its current and future development programs may enable the Company to utilize a regulatory pathway that would streamline clinical development and accelerate the path towards commercialization. Learn more at  www.zosanopharma.com .

Zosano Contact: Konstantinos Alataris, Ph.D. Chief Executive Officer 510-745-1200 Investor Contact: Jamien Jones Blueprint Life Science Group 415-375-3340 x 5 jjones@bplifescience.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Nonprofit and Partners Gift Homes to Veterans

Updated Category News Views 100

A Heartfelt Gesture on Veterans Day Now this is the kind of story that gets you right in the gut. On November 9, two veterans, who were likely walking into a golf club thinking it was just another evening, were handed the keys to a future they might have only dreamt of: a mortgage-free home. Operation Finally Home, backed by the big names like Lennar and the patriotic...

Continue Reading
Cardinal Infrastructure Faces Legal Scrutiny Amid Losses

Updated Category News Views 125

Cardinal Infrastructure Group Under Intense Investor Scrutiny Well, ain't this a messy soup of financial blunders? Cardinal Infrastructure Group (Nasdaq: CDNL) finds itself on the sharp end of a potential securities law investigation, thanks to some colossal screw-ups in managing project costs and estimates. Investors are rightly pissed after the company's shares...

Continue Reading
WeFetch AI: A New Era in Barcode Precision

Updated Category News Views 155

WeFetch AI: What's in a Name? Forget about GreenCore Solutions Corp. We're talking about WeFetch AI Corp. now. They've just changed their name, fulfilling a bureaucratic tick as of November 13, 2026. But it ain't just a name change; it's a whole new ballgame in AI-driven commerce. AI Shopping Without the Guesswork We've all been there. You think you've ordered that...

Continue Reading
Novo's CagriSema Trial Shows Promising Obesity Results

Updated Category News Views 103

Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...

Continue Reading
Retirement Dreams Dashed: 61% Withdraw Early

Updated Category News Views 97

Retirement Caught in the Crosshairs Just when you think the path to retirement might clear up, life slaps down older workers with economic reality. A recent LiveCareer survey underscores this financial mess, revealing that 61% of those 50 and older are raiding their own retirement funds to make ends meet. It's enough to make one's head spin. Inflation: The Unwanted Guest...

Continue Reading
DraftKings Shares Tumble, Investors Grapple with Losses

Updated Category News Views 60

DraftKings' Bold Moves Hit Investor Pockets Hard It ain't every day you see a company gamble nearly $700 million and come out with egg on its face. Yet, that's what DraftKings (NASDAQ: DKNG) seems to have done, and now it's shareholders who might be left holding the bag. On November 6, 2026, when DraftKings admitted it was doubling down on its Predictions business...

Continue Reading
BTQ Technologies Calls Investors for Key Quantum Update

Updated Category News Views 122

You know what's stirring the pot over at BTQ Technologies? A shareholder call coming up soon, and boy, it's got 'eye-opening insights' written all over it. We're talkin' Q3 financial results and, likely, a smattering of future plans on the quantum front, folks. Diving into BTQ's Quantum Vision BTQ Technologies Corp. (NASDAQ: BTQ) isn't just another tech firm banging on...

Continue Reading
SmallRig Boosts Art-Driven Innovation in AI Era

Updated Category News Views 106

The Interplay of Art and AI In a world where the lines between man and machine blur faster than ever, creators like SmallRig are boldly asking: what role should authenticity play when AI takes the stage? The Shenzhen International Art Museum and SmallRig stood shoulder to shoulder, tackling this head-scrambling question with a global gathering of art and tech giants. It's...

Continue Reading
GTEC Faces Nasdaq Bid Price Compliance Challenge

Updated Category News Views 154

Greenland Technologies in a Tight Spot Man, stocks can be as unpredictable as a cat on a hot tin roof, and Greenland Technologies Holding Corporation (Nasdaq: GTEC) just got a cold splash of reality from Nasdaq. On November 10, 2026, they were handed a Notification Letter that ain’t exactly a love note. Their shares slipped below the one-buck hurdle, and Nasdaq isn’t...

Continue Reading
Advanta's Game-Changer: Acquiring Misr Hytech to Expand in Africa

Updated Category News Views 96

Advanta's Strategic Move into Africa Alright, let's cut to the chase. Advanta is making a big splash with its acquisition of Misr Hytech, a move that's going to shake things up in Africa's agricultural sector. This isn't just another merger to gloss over with your morning coffee. We're talking about a deal that's supposed to wrap up by January 31, 2027, bringing together...

Continue Reading

Top 5 Most Recently Viewed Articles

Class Action Lawsuit Launched for iLearningEngines Investors

Updated Category News Views 92

Understanding the Class Action Lawsuit Against iLearningEngines Recently, iLearningEngines, Inc. (NASDAQ: AILE) has found itself at the center of a shareholder class action lawsuit. The legal action arises from allegations that the company made false and misleading statements that misrepresented its financial status. Investors are now scrutinizing the company's...

Continue Reading
FMC Corporation Shareholders Alert: Important Legal Action Notice

Updated Category News Views 103

Class Action Lawsuit Notification for FMC Shareholders The Gross Law Firm is reaching out to shareholders of FMC Corporation (NYSE: FMC) regarding a crucial class action lawsuit. This notice signifies important information for shareholders who may have purchased shares during a specified period. Enrollment for Shareholders If you acquired shares of FMC during the...

Continue Reading
QETAU Stock Reaches New Heights: Unveiling Market Trends

Updated Category News Views 186

QETAU Stock Achieves Record High Amid Market Enthusiasm In a remarkable display of market confidence, Quetta Acquisition Unit (QETAU) stock has reached an all-time high of $11. This milestone reflects a period of strong performance, indicating significant investor endorsement. Over the past year, QETAU has grown by 3.76%, demonstrating its upward trajectory in a dynamic...

Continue Reading
Nvidia's Growth Outlook Amidst Market Fluctuations

Updated Category News Views 231

Nvidia's Growth Outlook Amidst Market Fluctuations A look at the current trends in the market reveals some intriguing insights into Nvidia (NASDAQ: NVDA), the world's leading chip manufacturer and a key player in the artificial intelligence sector. Despite its impressive track record, analysts caution that the exceptionally high growth rates Nvidia has enjoyed can't last...

Continue Reading
Exciting Expansion of MariMed's Betty’s Eddies Brand with New Chews

Updated Category News Views 191

Innovative Growth in Edibles: Introducing Betty’s Caramelt Away Hailing from Norwood, Massachusetts, Betty’s Eddies™ is making waves in the cannabis industry with an exciting new product launch that caters to consumers' sweet cravings. The addition of Betty’s Caramelt Away, delicious caramel chews infused with THC and CBG, is transforming this beloved brand and...

Continue Reading